Dose-dependent effects of the once-daily GLP-1 receptor agonist lixisenatide in patients with Type 2 diabetes inadequately controlled with metformin: a randomized, double-blind, placebo-controlled trial

Randomized, double‐blind, placebo‐controlled trial of the once‐daily GLP ‐1 receptor agonist lixisenatide in Asian patients with type 2 diabetes insufficiently controlled on basal insulin with or without a sulfonylurea ( GetGoal ‐L‐Asia)

10.1111/j.1463-1326.2012.01618.x ◽

2012 ◽

Vol 14 (10) ◽

pp. 910-917 ◽

Cited By ~ 188

Author(s):

Y. Seino ◽

K. W. Min ◽

E. Niemoeller ◽

A. Takami ◽

Keyword(s):

Type 2 Diabetes ◽

Basal Insulin ◽

Receptor Agonist ◽

Controlled Trial ◽

Double Blind ◽

Once Daily ◽

Double Blind Placebo ◽

Asian Patients

Efficacy and Safety of the Once-Daily GLP-1 Receptor Agonist Lixisenatide in Monotherapy: A randomized, double-blind, placebo-controlled trial in patients with type 2 diabetes (GetGoal-Mono)

Diabetes Care ◽

10.2337/dc11-1935 ◽

2012 ◽

Vol 35 (6) ◽

pp. 1225-1231 ◽

Cited By ~ 154

Author(s):

V. A. Fonseca ◽

R. Alvarado-Ruiz ◽

D. Raccah ◽

G. Boka ◽

P. Miossec ◽

...

Keyword(s):

Type 2 Diabetes ◽

Receptor Agonist ◽

Controlled Trial ◽

Efficacy And Safety ◽

Double Blind ◽

Once Daily ◽

Effects of once-daily teneligliptin on 24-h blood glucose control and safety in Japanese patients with type 2 diabetes mellitus: a 4-week, randomized, double-blind, placebo-controlled trial

10.1111/j.1463-1326.2012.01662.x ◽

2012 ◽

Vol 14 (11) ◽

pp. 1040-1046 ◽

Cited By ~ 51

Author(s):

T. Eto ◽

S. Inoue ◽

T. Kadowaki

Keyword(s):

Diabetes Mellitus ◽

Type 2 Diabetes ◽

Type 2 Diabetes Mellitus ◽

Controlled Trial ◽

Blood Glucose Control ◽

Japanese Patients ◽

Double Blind ◽

Once Daily ◽

Erratum. Renal Effects of DPP-4 Inhibitor Sitagliptin or GLP-1 Receptor Agonist Liraglutide in Overweight Patients With Type 2 Diabetes: A 12-Week, Randomized, Double-Blind, Placebo-Controlled Trial. Diabetes Care 2016;39:2042–2050

Diabetes Care ◽

10.2337/dc19-er03 ◽

2019 ◽

Vol 42 (3) ◽

pp. 494.1-494 ◽

Cited By ~ 1

Author(s):

Lennart Tonneijck ◽

Mark M. Smits ◽

Marcel H.A. Muskiet ◽

Trynke Hoekstra ◽

Mark H.H. Kramer ◽

...

Keyword(s):

Type 2 Diabetes ◽

Diabetes Care ◽

Receptor Agonist ◽

Controlled Trial ◽

Double Blind ◽

Renal Effects ◽

Efficacy and safety of once-weekly glucagon-like peptide 1 receptor agonist albiglutide (HARMONY 1 trial): 52-week primary endpoint results from a randomized, double-blind, placebo-controlled trial in patients with type 2 diabetes mellitus not controlled

10.1111/dom.12382 ◽

2014 ◽

Vol 16 (12) ◽

pp. 1257-1264 ◽

Cited By ~ 62

Author(s):

J. Reusch ◽

M. W. Stewart ◽

C. M. Perkins ◽

D. T. Cirkel ◽

J. Ye ◽

...

Keyword(s):

Diabetes Mellitus ◽

Type 2 Diabetes ◽

Receptor Agonist ◽

Controlled Trial ◽

Efficacy And Safety ◽

Double Blind ◽

Double Blind Placebo ◽

Glucagon Like Peptide ◽

Glucagon Like Peptide 1

Acute renal effects of the GLP-1 receptor agonist exenatide in overweight type 2 diabetes patients: a randomised, double-blind, placebo-controlled trial

Diabetologia ◽

10.1007/s00125-016-3938-z ◽

2016 ◽

Vol 59 (7) ◽

pp. 1412-1421 ◽

Cited By ~ 55

Author(s):

Lennart Tonneijck ◽

Mark M. Smits ◽

Marcel H. A. Muskiet ◽

Trynke Hoekstra ◽

Mark H. H. Kramer ◽

...

Keyword(s):

Type 2 Diabetes ◽

Receptor Agonist ◽

Controlled Trial ◽

Double Blind ◽

Renal Effects ◽

Double Blind Placebo ◽

Diabetes Patients

Dose-dependent improvement in glycemia with once-daily liraglutide without hypoglycemia or weight gain: A double-blind, randomized, controlled trial in Japanese patients with type 2 diabetes

Diabetes Research and Clinical Practice ◽

10.1016/j.diabres.2008.03.018 ◽

2008 ◽

Vol 81 (2) ◽

pp. 161-168 ◽

Cited By ~ 79

Author(s):

Y. Seino ◽

M.F. Rasmussen ◽

M. Zdravkovic ◽

K. Kaku

Keyword(s):

Type 2 Diabetes ◽

Randomized Controlled Trial ◽

Weight Gain ◽

Controlled Trial ◽

Japanese Patients ◽

Double Blind ◽

Once Daily ◽

Randomized Controlled ◽

Dose Dependent

Renal Effects of DPP-4 Inhibitor Sitagliptin or GLP-1 Receptor Agonist Liraglutide in Overweight Patients With Type 2 Diabetes: A 12-Week, Randomized, Double-Blind, Placebo-Controlled Trial

Diabetes Care ◽

10.2337/dc16-1371 ◽

2016 ◽

Vol 39 (11) ◽

pp. 2042-2050 ◽

Cited By ~ 50

Author(s):

Lennart Tonneijck ◽

Mark M. Smits ◽

Marcel H.A. Muskiet ◽

Trynke Hoekstra ◽

Mark H.H. Kramer ◽

...

Keyword(s):

Type 2 Diabetes ◽

Receptor Agonist ◽

Controlled Trial ◽

Double Blind ◽

Renal Effects ◽

Efficacy and safety of linagliptin 2.5 mg twice daily versus 5 mg once daily in patients with type 2 diabetes inadequately controlled on metformin: a randomised, double-blind, placebo-controlled trial

Current Medical Research and Opinion ◽

10.1185/03007995.2012.714360 ◽

2012 ◽

Vol 28 (9) ◽

pp. 1465-1474 ◽

Cited By ~ 30

Author(s):

Stuart A. Ross ◽

Elizabeth Rafeiro ◽

Thomas Meinicke ◽

Robert Toorawa ◽

Sonja Weber-Born ◽

...

Keyword(s):

Type 2 Diabetes ◽

Controlled Trial ◽

Efficacy And Safety ◽

Double Blind ◽

Once Daily ◽

Metabolic improvement with short‐term glucagon like peptide‐1 receptor agonist treatment does not improve cardiac diastolic dysfunction in patients type 2 diabetes: a randomized double‐blind placebo‐controlled trial

10.1111/dom.14480 ◽

2021 ◽

Author(s):

Annemie Stege Bojer ◽

Martin Heyn Sørensen ◽

Jenny Bjerre ◽

Peter Gæde ◽

Niels Vejlstrup ◽

...

Keyword(s):

Type 2 Diabetes ◽

Diastolic Dysfunction ◽

Receptor Agonist ◽

Controlled Trial ◽

Short Term ◽

Double Blind ◽

Double Blind Placebo ◽

Glucagon Like Peptide ◽

Glucagon Like Peptide 1